ANTI- HYPERTENSIVE AGENTS

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "ANTI- HYPERTENSIVE AGENTS"

Transcription

1 CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is the most common treatable risk factor for cardiovascular disease in patients over the age of 50 years. A clear relationship exists between elevated blood pressure (BP) and the various manifestations of cardiovascular disease. See Expand your Portfolio on page 65 The new target Although blood pressure reduction is undoubtedly beneficial, it is important to emphasise at the outset that the concept of single risk factor intervention has been challenged by the recognition that the real target is cardiovascular disease risk. From an evidence-based perspective, the new target is cardiovascular risk and not its individual components. The importance of lifestyle in hypertension Despite the availability of a myriad of effective antihypertensive agents, a healthy lifestyle remains the cornerstone of the management of hypertension. A healthy lifestyle: Decreases blood pressure Improves antihypertensive medicine efficacy Reduces cardiovascular risk The risk of cardiovascular disease can be reduced by increasing consumption of fresh fruits and vegetables, fish and fish oils, as well as by moderate intensity physical activity and a low to moderate alcohol intake. The effects of various lifestyle interventions in reducing systolic blood pressure (SBP) are shown in Table 1. Table 1: The effects of lifestyle interventions on SBP reduction (Adapted from South African Hypertension guideline 2006) Intervention Reduce weight Reduce salt intake Restrict alcohol consumption Increase fruit and vegetable consumption Physical activity Stop tobacco use Recommendation Maintain normal body weight (Body Mass Index kg/m 2 ) Reduce salt intake to 6 g or less per day (equivalent to 2.4 g sodium) Limit consumption to 2 standard * drinks per day in men and 1 standard drink a day in women Do not drink alcohol every day Increase fruit, vegetables, legumes to 5 or more helpings a day Exercise for at least 30 minutes on most days of the week (minimum 150 minutes/ week) Approximate SBP reduction 5 20 mm Hg/10 kg weight loss 2 8 mm Hg 2 4 mm Hg Reduces stroke by up to 26% 4 9 mm Hg * A standard drink contains approx. 10 g ethanol (e.g. 25 ml spirits/liqueur, 125 ml wine, 340 ml beer, 60 ml sherry). 22 SA Pharmaceutical Journal April 2008

2 SA Pharmaceutical Journal April

3 CLINICAL When should antihypertensive therapy be initiated in the patient with hypertension? Pharmacotherapy for hypertension should be commenced: In patients at low added risk despite a period of 6-12 months of lifestyle modification and observation. In patients at moderate added risk despite a period of 3-6 months of lifestyle modification and observation. In patients at high or very high added risk. See Figure 1 and Tables 2 and 3 for risk stratification of patients. The treatment of hypertension is based on the above risk stratification of the patient as assessed using Tables 2 and 3. See Figure 1. Table 2: Major risk factors for cardiovascular disease, target-organ damage and associated clinical conditions (Adapted from SA Hypertension guideline 2006) Major risk factors Levels of systolic and diastolic blood pressure Dyslipidaemia Total cholesterol > 6.5 mmol/l OR LDL > 4 mmol/l OR HDL < 1 mmol/l for men and < 1.2 mmol/l for women Diabetes mellitus Men > 55 years Women > 65 years Smoking Family history of early onset of CVD Men < 55 years Women < 65 years Waist circumference Men 102 cm and women 88 cm Target-organ damage Left ventricular hypertrophy Microalbuminuria: albumin / creatinine ratio 3-30 mg/mmol Slightly elevated creatinine Men umol/l Women umol/l Associated clinical conditions Coronary heart disease Chronic kidney disease Albumin/creatinine ratio > 30 mg/mmol Stroke or transient ischaemic attack Advanced retinopathy haemorrhages OR exudates OR papilloedema Peripheral arterial disease Table 3: Stratification of risk (Adapted from SA Hypertension guideline 2006) BP (mm Hg) Normal High-normal Stage 1 Mild HT Stage 2 Moderate HT Stage 3 Severe HT SBP or DBP SBP or DBP SBP or DBP SBP or DBP SBP > 180 or DBP > 110 Other risk factors No other major risk factors Average risk Average risk Low added risk Moderate added risk High added risk 1-2 major risk factors Low added risk Low added risk Moderate added risk Moderate added risk 3 major risk factors or TOD or DM Moderate added risk High added risk High added risk High added risk Associated clinical conditions High added risk KEY: TOD = Target-organ damage; DM = Diabetes mellitus Figure 1: Risk stratification of patients LOW ADDED RISK MODERATE ADDED RISK HIGH/VERY HIGH ADDED RISK LIFESTYLE MODIFICATION AS APPROPRIATE Monitor BP and other risk factors for 6 12 months Monitor BP and other risk factors for 3 6 months SBP 140 or DBP 90 SBP < 140 or DBP < 90 SBP < 140 or DBP < 90 SBP 140 or DBP 90 CONTINUE TO MONITOR BEGIN DRUG TREATMENT 24 SA Pharmaceutical Journal April 2008

4 SA Pharmaceutical Journal April

5 CLINICAL What is the target BP level that the patient with hypertension should aim for? Target blood pressure levels for patients with hypertension depend on the patient s risk factors, the presence of target-organ damage and the presence of associated clinical conditions. See Table 2. Which antihypertensive should be selected? Recent studies have led to a reconsideration of the medicines of choice for the management of uncomplicated hypertension. There are three important classes of antihypertensive agents for the management of hypertension in patients with uncomplicated hypertension: Diuretics thiazide and thiazide-like Angiotensin-converting enzyme inhibitors (ACE-Is) and Calcium channel blockers The treatment of uncomplicated hypertension as recommended by the South African Hypertension guideline 2006, is as follows: Step 1 Initiate therapy with low-dose hydrochlorothiazide (12.5 mg up to a maximum of 25 mg) or a thiazide-like diuretic. Higher doses are not recommended because of the risk of new diabetes. Low-dose diuretics are the most effective first-line antihypertensive therapy and are less expensive. Low-dose diuretics are also the first-line therapy for older patients. Step 2 and 3 Where there are no other compelling indications, then one of the following is recommended as second- or third-line therapy: - ACE inhibitor (or an angiotensinll receptor blocker (ARB) in the case of ACE inhibitor intolerance) - A calcium channel blocker (longacting dihydropyridines or nondihydropyridines). Note: Short-acting calcium channel blockers are not recommended for the management of hypertension. Most people will require more than one antihypertensive agent to control blood pressure. Combination therapy may be provided as separate products or as a Stage All stages of hypertension High-risk patients e.g. those with diabetes mellitus, renal disease or congestive heart failure fixed-dose combination product. The latter has an advantage of allowing BP control to be achieved with a reduced number of daily tablets so that patient adherence to therapy is improved. Effective antihypertensive combinations are: Diuretic plus ACE inhibitor (or ARB) Calcium channel blocker with ACE inhibitor (or ARB) Beta blocker with alpha blockade Diuretic plus beta-blocker * Note: * While a diuretic-beta-blocker combination comprises effective combination therapy, the combination of a thiazide diuretic with a beta-blocker should be discouraged as both classes of antihypertensives have potentially adverse metabolic consequences and increase the risk of new onset diabetes. Patients with certain pre-existing medical conditions may be preferentially managed using certain antihypertensive agents, while other antihypertensive agents may be contraindicated. The table below lists the compelling indications as well as possible and compelling contraindications. More about the antihypertensive agents Thiazide and thiazide-like diuretics Thiazides and related agents are firstline medicines in the treatment of hypertension. The thiazides are sulphonamide derivatives. They act by inhibition of sodium and chloride reabsorption at proximal sites of the distal renal tubules. The antihypertensive effect is of slow onset, requiring up to two months for full effect. In hypertension, the thiazide diuretics may be used alone, in combination with a potassium-sparing diuretic or with other antihypertensive agents. The antihypertensive effect is enhanced by a low-salt diet The thiazides and thiazide-like diuretics are contraindicated in patients allergic to sulphonamides. Table 4: Blood pressure target levels (Adapted from SA Hypertension guideline 2006) BP Target (mm Hg) < 140/90 < 130/80 Comment In isolated systolic hypertension, do not lower the DBP to < 65 mm Hg Ideally these target levels should be reached within three months The maximum antihypertensive dose is 25 mg of hydrochlorothiazide (or equivalent) per day. Electrolyte imbalances are the most frequently occurring major adverse effects. Hypokalaemia does not necessarily cause symptoms. However, hypokalaemia and hypomagnesaemia potentiate digoxin toxicity in patients receiving digoxin therapy. Potassium and magnesium supplementation may be necessary. ACE-inhibitors ACE-inhibitors act by preventing the conversion of angiotensin l to angiotensin ll (a powerful vasoconstrictor). There are several ACE-inhibitors available and all are considered safe and effective in the treatment of hypertension. A low salt diet with concurrent diuretic therapy enhances the antihypertensive effect. In black patients, the ACE-inhibitors are considered less effective in the absence of concurrent diuretic therapy. In hypertensive patients under the age of 55 years, an ACE-inhibitor or an ARB may be considered for initial therapy. ACE-inhibitors may cause rapid reductions in blood pressure. Therefore, initiate therapy with a low dose, especially in patients receiving diuretics. Renal function and electrolytes should be checked before starting therapy and monitored during treatment. All ACE-inhibitors are contraindicated in pregnancy. Cough, the most common adverse effect may respond to a decreased dose or may resolve with continued treatment. 26 SA Pharmaceutical Journal April 2008

6 SA Pharmaceutical Journal April

7 CLINICAL Table 5: Compelling indications and contraindications for the use of antihypertensives Class Diuretics (thiazide; thiazidelike)(low-ceiling diuretics) Diuretics (loop) e.g. furosemide (high-ceiling diuretics) Diuretics (aldosterone antagonist) e.g. spironolactone (potassium-sparing diuretics) Calcium channel blocker (longacting dihydropyridine) e.g. amlodipine Calcium channel blocker (non dihydropyridine) e.g. verapamil; diltiazem ACE inhibitors e.g. enalapril ARBs e.g. losartan Beta blockers e.g. carvedilol, bisoprolol Indications Elderly hypertensives Isolated systolic hypertension Black hypertensives Renal insufficiency Post myocardial infarction Resistant hypertension Elderly hypertensives Isolated systolic hypertension Angina pectoris Peripheral vascular disease Carotid atherosclerosis Black hypertensives Angina pectoris Carotid atherosclerosis Supraventricular tachycardia Left ventricular dysfunction Post myocardial infarction Non-diabetic nephropathy Type 1 diabetic nephropathy Type 2 diabetes mellitus Proteinuria Type 2 diabetic nephropathy Type 2 diabetic microalbuminuria Proteinuria Left ventricular hypertrophy ACE inhibitor cough or intolerance Angina pectoris Post myocardial infarction (only selected beta blockers e.g. carvedilol) Tachyarrhythmias Gout Compelling Not used in other hypertensive patients Renal failure Hyperkalaemia Atrioventricular block (grade 2 or 3) Hyperkalaemia Bilateral renal artery stenosis Hyperkalaemia Bilaterial renal artery stenosis Asthma Chronic obstructive pulmonary disease Atrioventricular block (grade 2 or 3) Contraindications Possible Concurrent use with a beta blocker Tachyarrhythmias Concurrent antiretroviral therapy Constipation (verapamil) Concurrent antiretroviral therapy Peripheral vascular disease Bradycardia Glucose intolerance Metabolic syndrome Athletes and physically active patients Concurrent use with nondihydropyridine calcium channel blockers Angioedema is a rare major side effect that contraindicates the future use of other ACE inhibitors and angiotensin ll receptor blockers. Use with caution in patients taking potassium-sparing diuretics or potassium supplements as serious hyperkalaemia may occur. Angiotensin ll receptor blockers (ARBs) This class of antihypertensives inhibits the effect of angiotensin ll on its receptor (the AT1 receptor) and block angiotensinll-induced vasoconstriction. The ARBs have many properties similar to the ACEinhibitors, except they do not inhibit the breakdown of bradykinin and other kinins and thus do not cause the persistent dry cough that commonly complicates ACE-inhibitor therapy. The ARBs are therefore a useful alternative for patients who have to discontinue an ACEinhibitor because of persistent cough. Dose-related hypotension may occur, especially in patients receiving diuretics. Like the ACE-inhibitors, the ARBs are contraindicated in pregnancy. Use with caution, if at all, in patients who have previously experienced angioedema with an ACE-inhibitor. Hyperkalaemia may occur. Potassium levels should be monitored, especially in the elderly and in patients with renal impairment. Concurrent use with potassium-sparing diuretics or potassium supplements should generally be avoided. Calcium channel blockers Calcium channel blockers (CCBs) interfere with the inward displacement of calcium ions through the slow channels of 28 SA Pharmaceutical Journal April 2008

8 SA Pharmaceutical Journal April

9 CLINICAL active cell membranes. They influence the myocardial cells, the cells within the specialised conducting system of the heart and the cells of vascular smooth muscle. Calcium channel blockers vary in their predilection for these various possible sites of action and therefore, in their therapeutic effects. There are important differences between verapamil, diltiazem and dihydropyridine calcium channel blockers used in hypertension e.g. amlodipine, isradipine, felodipine. In the treatment of hypertension, the dominant effect is a decrease in peripheral vascular resistance. Short-acting nifedipine has been associated with adverse myocardial outcomes and should not be used in the treatment of hypertension. The elderly patient may be preferentially treated with a calcium channel blocker alone or in combination with a thiazide diuretic. Calcium channel blockers should not be used together with alpha-blockers as severe hypotension may occur. The combination of a CCB and a beta-blocker should also be used with caution. The most common adverse effects include headache, flushing, dizziness and light-headedness. Serious cardiac adverse effects are rare. Beta-blockers Beta-blockers block beta-adrenoreceptors, primarily in the heart, bronchi, peripheral vasculature, pancreas and liver. The mechanism of action in hypertension is not clear but may include reduction of cardiac output, altered baroreceptor reflex sensitivity, depression of plasma renin and decreased release of neurotransmitters such as noradrenaline. Certain beta blockers (such as atenolol) are no longer considered as routine treatment for patients with uncomplicated hypertension, in view of several major considerations, including the failure of atenolol-based therapy in the ASCOT-BPLA * study. Beta-blockers do not reduce cardiovascular mortality or myocardial infarct mortality when given for hypertension. Betablockers may precipitate new onset diabetes, especially when used with diuretics. Note:The newer beta-blockers such as carvedilol, bisoprolol and nebivolol were not included in the two large meta-analyses of the effects of beta-blockers when used for hypertension. Carvedilol is a nonspecific adrenergic receptor blocker, blocking not only beta-1 and beta-2 receptors but alpha-receptors as well. * ASCOT-BPLA compared the effect on non-fatal myocardial infarction (MI) and fatal CHD of atenolol with a thiazide diuretic and amlodipine with perindopril. ASCOT-BPLA suggests that atenolol is not an acceptable initial therapy for hypertension and that an initial strategy using a calcium channel blocker is more effective. While beta-blocker therapy will continue to be used in patients with a compelling indication (See Table 5) for their use e.g. in post myocardial infarction, it is recommended that the use of atenolol as initial therapy or as initial combination therapy in the treatment of hypertension, should be restricted. Alpha-blockers Alpha-blockers have post-synaptic alphablocking and vasodilator properties. These agents are not used as first-line therapy but may be added to treatment with other antihypertensives. They may, however, be useful for patients with diabetes mellitus or lipid disorders. The hypotensive effects may be pronounced, especially in the elderly, and therefore treatment should be initiated slowly. In conclusion Pharmacotherapy to lower blood pressure is worthwhile, even if the blood pressure does not reach the targets defined in Table 4. Lifestyle modifications are difficult to sustain and therefore it is important to offer patients with hypertension ongoing support, regular blood pressure monitoring and advice on the appropriate use of antihypertensive medication. References: 1. Laurent S. Guidelines from the British Hypertension Society. BMJ 2004;328: Joint National Hypertension Guideline Working Group. South African Hypertension Guideline SAMJ 2006;96(4): Williams B. Recent hypertension trials Implications and controversies. J Am Coll Cardiol 2005;45(6): Eds. South African Medicines Formulary 7 th Ed Eds. British National Formulary. 48 th Ed NICE Clinical Guideline SA Pharmaceutical Journal April 2008

10 SA Pharmaceutical Journal April

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit

More information

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 Hypertension in adults: diagnosis and management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

Chapter (9) Calcium Antagonists

Chapter (9) Calcium Antagonists Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug

More information

DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)

DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples

More information

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias

1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias 1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Five chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical

More information

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have

More information

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease

More information

Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents

Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents Complete the following. 1. A layer of cells lines each vessel in the vascular system. This layer is a passive barrier that keeps cells and proteins from going into tissues; it also contains substances

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

LXIV: DRUGS: 4. RAS BLOCKADE

LXIV: DRUGS: 4. RAS BLOCKADE LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations

More information

Should beta blockers remain first-line drugs for hypertension?

Should beta blockers remain first-line drugs for hypertension? 1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

Hypertension Management Focus on new RAAS blocker. Disclosure

Hypertension Management Focus on new RAAS blocker. Disclosure Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay

More information

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Chronic Benefit Application Form Cardiovascular Disease and Diabetes Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)

More information

Abbreviations Cardiology I

Abbreviations Cardiology I Cardiology I and Clinical Controversies Joseph J. Saseen, Pharm.D., FCCP, BCPS (AQ Cardiology) Reviewed by Stuart T. Haines, Pharm.D., FCCP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning

More information

신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure

신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure 신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of

More information

Metabolic Syndrome and Chronic Kidney Disease

Metabolic Syndrome and Chronic Kidney Disease Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference

More information

Drug Class Review on Calcium Channel Blockers FINAL REPORT

Drug Class Review on Calcium Channel Blockers FINAL REPORT Drug Class Review on Calcium Channel Blockers FINAL REPORT September 2003 TABLE OF CONTENTS Introduction 5 Scope and Key Questions 6 Methods 6 Literature Search 6 Study Selection 6 Data Abstraction 7 Validity

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel

More information

HYPERTENSION. Shelby Bublitz Winter Quarter 2015 Cory Ruth NTRS 415A-03 Shelly Truong Professor Owen

HYPERTENSION. Shelby Bublitz Winter Quarter 2015 Cory Ruth NTRS 415A-03 Shelly Truong Professor Owen HYPERTENSION Shelby Bublitz Winter Quarter 2015 Cory Ruth NTRS 415A-03 Shelly Truong Professor Owen What exactly is HYPERTENSION? Blood pressure is affected either by peripheral resistance or cardiac output.

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Byvalson. (nebivolol, valsartan) New Product Slideshow

Byvalson. (nebivolol, valsartan) New Product Slideshow Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength

More information

ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ

ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ CAD: Statistics CAD is the largest killer of American males and females 13 million Americans have CAD 1.1 million MI s per year Every 26 seconds an American

More information

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with

More information

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.

More information

Amlodipine plus Lisinopril Tablets AMLOPRES-L

Amlodipine plus Lisinopril Tablets AMLOPRES-L Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

HTA. UMF Gatineau. Dr Tinouch Haghighat Cardiologue CSSSG-Hull

HTA. UMF Gatineau. Dr Tinouch Haghighat Cardiologue CSSSG-Hull HTA UMF Gatineau Dr Tinouch Haghighat Cardiologue CSSSG-Hull Leading diagnoses resulting in visits to physician offices in Canada 25 20 15 10 Million visits/year Hypertension Depression Diabetes Routine

More information

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests www.bpac.org.nz keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests Why do we monitor patients taking diuretics and what do we monitor? Monitoring a person on

More information

Guide to the New Hypertension Guidelines. LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital

Guide to the New Hypertension Guidelines. LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital Guide to the New Hypertension Guidelines LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital Disclosures None Objectives Describe the new hypertension staging and blood pressure goals and

More information

Metoprolol Succinate SelokenZOC

Metoprolol Succinate SelokenZOC Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic

More information

Role of Sympathetic Nervous System in Hypertension

Role of Sympathetic Nervous System in Hypertension Role of Sympathetic Nervous System in Hypertension BP = CO x PVR SV HR DEFENSE REACTION Suppressed vagal activity Increased sympathetic activity to heart, veins, kidneys, splachnic region, skin Skeletal

More information

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1

More information

Blood Pressure Treatment in 2018

Blood Pressure Treatment in 2018 Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management

More information

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014 HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted

More information

Use of Beta-blocker Monotherapy in Hypertension: Situation in a Local General Outpatient Clinic

Use of Beta-blocker Monotherapy in Hypertension: Situation in a Local General Outpatient Clinic Use of Beta-blocker Monotherapy in Hypertension: Situation in a Local General Outpatient Clinic Dr. Dao Man Chi Resident Department of Family Medicine and Primary Health Care, KWC HA Convention 2014 Introduction

More information

Antihypertensive Combinations

Antihypertensive Combinations This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations

More information

Hypertension Management in Diabetic Patients

Hypertension Management in Diabetic Patients Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension

More information

This Protocol is applicable to Class 1, 2, and Class 3 applicants. Resting ECG shall be performed at the following intervals:

This Protocol is applicable to Class 1, 2, and Class 3 applicants. Resting ECG shall be performed at the following intervals: SCHEDULE 34: PROTOCOL ON ELECTROCARDIOGRAMS ( ECG ) 1. Applicability This Protocol is applicable to Class 1, 2, and Class 3 applicants. 2. Resting ECG Resting ECG shall be perfmed at the following intervals:

More information

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

APPENDIX D: PHARMACOTYHERAPY EVIDENCE Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991

More information

ACE. Inhibitors. Quiz feedback

ACE. Inhibitors. Quiz feedback ACE Inhibitors Quiz feedback bpac nz better medicin e bpac nz Quiz feedback, ACE inhibitors, 2006 Best Practice Advocacy Centre ACE inhibitors quiz feedback bpac nz Development Team: Rachael Clarke Sonia

More information

Prevention of Heart Failure: What s New with Hypertension

Prevention of Heart Failure: What s New with Hypertension Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults

More information

Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?

Metabolic Consequences of Anti Hypertensives: Is It Clinically Important? Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme

More information

Hypertension in Clinical Practice. Abeer Al Saweer, MBBS, Arab Board*

Hypertension in Clinical Practice. Abeer Al Saweer, MBBS, Arab Board* 1 Bahrain Medical Bulletin, Vol. 33, No. 1, March 2011 Education-Family Physician Corner Hypertension in Clinical Practice Abeer Al Saweer, MBBS, Arab Board* The global incidence of hypertension is growing.

More information

High blood pressure and stroke

High blood pressure and stroke Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk High blood pressure and stroke High blood pressure usually has no symptoms, but it is a contributing factor in around half of all strokes,

More information

Heart Failure Pharmacotherapy An Update

Heart Failure Pharmacotherapy An Update Heart Failure Pharmacotherapy An Update Kenneth Mishler, PharmD, MBA Objectives Review the epidemiology of heart failure (HF) Review evidence based guidelines for the use of mediations used to treat HF

More information

Talking about blood pressure

Talking about blood pressure Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight

More information

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered

More information

UPDATED MANAGEMENT OF HYPERTENSION IN ADULTS AT PRIMARY CARE LEVEL

UPDATED MANAGEMENT OF HYPERTENSION IN ADULTS AT PRIMARY CARE LEVEL NATIONAL GUIDELINE PRIMARY CARE LEVEL UPDATED MANAGEMENT OF HYPERTENSION IN ADULTS AT PRIMARY CARE LEVEL DEPARTMENT OF HEALTH DIRECTORATE:CHORNIC DISEASES, DISABILITIES AND GERIATRICS December 2006 TABLE

More information

HYPERTENSION 4.0 Contact Hours Presented by: CEU Professor

HYPERTENSION 4.0 Contact Hours Presented by: CEU Professor HYPERTENSION 4.0 Contact Hours Presented by: CEU Professor 7 www.ceuprofessoronline.com Copyright 8 2007 The Magellan Group, LLC All Rights Reserved. Reproduction and distribution of these materials is

More information

Summary/Key Points Introduction

Summary/Key Points Introduction Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification

More information

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI Hypertension, Hyperlipidemia and Obesity Mi-CCSI Objectives Review the prevalence of hypertension, hyperlipidemia and obesity Correlation of the 3 conditions Discuss why it is important to treat these

More information

Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris

Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments

More information

The Road to Renin System Optimization: Renin Inhibitor

The Road to Renin System Optimization: Renin Inhibitor The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension

More information

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients. Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded

More information

Executive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1

Executive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 IQWiG Reports Commission No. A05-09 Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 Executive Summary 1 Translation of the executive summary of the final

More information

Creative blood pressure management: whys and the tricks

Creative blood pressure management: whys and the tricks Creative blood pressure management: whys and the tricks Cynthia D. Caraballo-Hunt, MD Kaiser/OHSU Family Medicine Faculty Beaverton Medical Office NW Permanente, Portland, OR Objectives 1. Describe current

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Hypertension and the JNC-8 guidelines

Hypertension and the JNC-8 guidelines What goes up must come down: Hypertension and the JNC-8 guidelines What you need to know about the new treatment guidelines By Terri Townsend, MA, RN, CCRN-CMC, CVRN-BC, and Pamela Anderson, MS, RN, ANP-BC,

More information

The role of physical activity in the prevention and management of hypertension and obesity

The role of physical activity in the prevention and management of hypertension and obesity The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity

More information

Choice of therapy in esse... http://www.uptodate.co... Page 1 of 28 Official reprint from UpToDate www.uptodate.com Print Back Choice of therapy in essential hypertension: Recommendations Authors Norman

More information

Guideline-Directed Medical Therapy

Guideline-Directed Medical Therapy Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:

More information

Structure and organization of blood vessels

Structure and organization of blood vessels The cardiovascular system Structure of the heart The cardiac cycle Structure and organization of blood vessels What is the cardiovascular system? The heart is a double pump heart arteries arterioles veins

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

METOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets

METOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets METOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets COMPOSITION Each film-coated tablet of Metotrust XL-25 contains: Metoprolol Succinate USP 23.75 mg equivalent to Metoprolol Tartrate 25

More information

Angina Pectoris Dr. Shariq Syed

Angina Pectoris Dr. Shariq Syed Angina Pectoris Dr. Syed 1 What is Angina Pectoris (AP)? Commonly known as angina is chest pain often due to ischemia of the heart muscle, Because of obstruction or spasm of the coronary arteries 2 What

More information

DOI: /jch.12237

DOI: /jch.12237 ASH PAPER Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension Michael A. Weber,

More information

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College

More information

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers. Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS

More information

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy Assessment Prior to administration: Assess patient for chest pain, dysrhythmias, and vital signs (initially and throughout therapy) Obtain complete medical history, including allergies, especially heart

More information

Randomized Design of ALLHAT BP Trial

Randomized Design of ALLHAT BP Trial Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive

More information

Antihypertensive Agents

Antihypertensive Agents 1. Blood Pressure Regulation Antihypertensive Agents - 2007 Edward JN Ishac. Ph.D. Associate Professor, Dept. Pharmacology & Toxicology Office: Smith 742; Tel: 828 2127 eishac@hsc.vcu.edu Frank's formula,

More information

Reducing risk in heart disease

Reducing risk in heart disease Reducing risk in heart disease An expert guide to clinical practice for secondary prevention of coronary heart disease Prof Patricia Davidson (chair) Prof Nigel Stocks Dr Anu Aggarwal Ms Jill Waddell Ms

More information

Chapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy

Chapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias

More information

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:

More information

Hypertension Putting the Guidelines into Practice. Andy Ignaszewski MD FRCPC UBC/PHC Cardiology

Hypertension Putting the Guidelines into Practice. Andy Ignaszewski MD FRCPC UBC/PHC Cardiology Hypertension 2017 Putting the Guidelines into Practice Andy Ignaszewski MD FRCPC UBC/PHC Cardiology Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION PERINDOPRIL ARGININE/AMLODIPINE (Viacoram Servier Canada Inc.) Indication: Mild to Moderate Essential Hypertension Recommendation: The Canadian

More information

ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration

ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication and Symptomatic HF despite ACEI/ARB and B-blocker therapy Bilateral renal artery stenosis Moderate/Severe

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information